NeoImmuneTech

Immunotherapy

Also 10 additional trials Clin1/Clin2 multiple cancers, Clin1 COVID-19, Clin1 vaccine adjuvant (ODD), Clin1 multifocal leukoencephalopathy; Clin0 idiopathic CD4 lymphocytopenia (ODD), Clin0 acute radiation syndrome

NeoImmuneTech is a clinical-stage biopharmaceutical company creating innovative T cell therapies that harness the immune system to target and destroy cancer cells. They are dedicated to discovering and developing novel immunotherapeutics to improve therapeutic options in immuno-oncology and infectious diseases. Their therapeutic approach modifies T cells response by inducing their activation, enhancing their response, and facilitating engagement with target cancer cells. Their heterodimer Fc drug development platform, called NEOBASE, allows for rapid development of multi-specific antibodies with increased stability and efficacy. This platform is used to enhance the body’s immune response through the improvement of protein function.